Physician profile
Sheldon M Wasserman
NPI 1255345625
$3,445.81
in general payments reported to CMS, 2019-2025
26 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $257 · 2021: $640 · 2022: $273 · 2023: $435 · 2024: $418 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $990.49 | 2019-2025 | |
| Abbvie INC. | $928.15 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Acadia Pharmaceuticals INC | $220.08 | 2019-2021 | |
| Allergan, INC. | $158.24 | 2019-2021 | |
| Lilly USA, LLC | $152.04 | 2019-2020 | |
| Genentech USA, INC. | $127.19 | 2019-2025 | Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $91.73 | 2021 | |
| Celgene Corporation | $80.88 | 2022-2024 | Zeposia |
| Biogen, INC. | $73.23 | 2019 | |
| Mdd US Operations, LLC | $71.13 | 2019 | |
| Grifols USA, LLC | $67.81 | 2023 | Gamunex-C |
| Lundbeck LLC | $64.04 | 2023-2024 | Vyepti |
| Avanir Pharmaceuticals, INC. | $61.29 | 2019 | |
| Acorda Therapeutics, INC | $44.04 | 2019-2023 | Inbrija |
| Adamas Pharmaceuticals, INC. | $42.64 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $38.22 | 2019 | |
| Emd Serono, INC. | $36.31 | 2019 | |
| Sk Life Science, INC. | $29.26 | 2024 | |
| Janssen Pharmaceuticals, INC | $26.68 | 2020 | |
| Tg Therapeutics, INC. | $24.58 | 2024 | |
| Nevro Corp. | $23.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.90 | 2020 | |
| Genzyme Corporation | $20.32 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.